Transaction DateRecipientSharesTypePriceValue
14th September 2020John D Forsyth310Open or private sale$83.59$25,912.90
14th September 2020John D Forsyth310Exercise of derivative$31.26$9,690.60
3rd September 2020Amy Mc Bride Wendell2,591Grant/award etc.$11.75$30,444.25
1st September 2020James W Borzi12,000Grant/award etc.$0.00
1st September 2020Cristiano Franzi1,132Payment by withholding$85.55$96,842.60
28th August 2020Point Llc Third10,421,052Other acquisition or disposition$0.00
28th August 2020Point Llc Third6,421,052Open or private purchase$9.50$60,999,994.00
3rd August 2020James R Iii Gavin10,789Exercise of derivative$37.50$404,587.50
3rd August 2020James R Iii Gavin3,351Open or private sale$86.91$291,235.41
3rd August 2020James R Iii Gavin4,110Exercise of derivative$39.83$163,701.30
Baxter International
Baxter International logo

Baxter International, Inc. provides portfolio of essential renal and hospital products. It operates through the following segment: Americas, Europe, Middle East & Africa and Asia-Pacific. The company was founded by Davis Baxter in 1931.

Ticker: BAX
Sector: Healthcare
Industry: Medical Instruments & Supplies
SEC Central Index Key (CIK): 10456
Employees: 50000
Exchange: New York Stock Exchange
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $4 B (0%)
Inventory, Net: $2 B (0%)
Assets, Current: $9 B (14%)
Property, Plant and Equipment, Net: $4 B (0%)
Other Assets, Noncurrent: $1 B (9%)
Assets: $19 B (6%)
Short-term Debt: $1 M (-99%)
Liabilities, Current: $3 B (-10%)
Other Liabilities, Noncurrent: $2 B (8%)
Liabilities: $11 B (9%)
Common Stock, Value, Issued: $683 M (0%)
Common Stock, Shares, Issued: $683 M (0%)
Additional Paid in Capital, Common Stock: $6 B (0%)
Retained Earnings (Accumulated Deficit): $16 B (2%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $4 B (7%)
Treasury Stock, Value: $106 Th (-1%)
Treasury Stock, Shares: $2 B (-2%)
Stockholders' Equity (Parent): $8 B (3%)
Liabilities and Equity: $19 B (6%)
Revenue: $3 B (0%)
Cost of Revenue: $2 B (-49%)
Gross Margin: $1 B (-52%)
Research and Development: $117 M (-55%)
Restructuring Charges: $7 M (-78%)
Operating Income/Loss: $331 M (0%)
Provision for income taxes: $42 M (-51%)
EPS (basic): $0.48 (-57%)
EPS (diluted): $0.48 (-57%)